BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22078245)

  • 1. C1-esterase inhibitor protects against early vein graft remodeling under arterial blood pressure.
    Krijnen PA; Kupreishvili K; de Vries MR; Schepers A; Stooker W; Vonk AB; Eijsman L; Van Hinsbergh VW; Zeerleder S; Wouters D; van Ham M; Quax PH; Niessen HW
    Atherosclerosis; 2012 Jan; 220(1):86-92. PubMed ID: 22078245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical HDL administration reduces vein graft atherosclerosis in apo E deficient mice.
    Feng Y; Gordts SC; Chen F; Hu Y; Van Craeyveld E; Jacobs F; Carlier V; Feng Y; Zhang Z; Xu Q; Ni Y; De Geest B
    Atherosclerosis; 2011 Feb; 214(2):271-8. PubMed ID: 20943224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor.
    Eefting D; de Vries MR; Grimbergen JM; Karper JC; van Bockel JH; Quax PH
    J Vasc Surg; 2010 Feb; 51(2):429-37. PubMed ID: 20036101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial Blood Pressure Induces Transient C4b-Binding Protein in Human Saphenous Vein Grafts.
    Kupreishvili K; Meischl C; Vonk ABA; Stooker W; Eijsman L; Blom AM; Quax PHA; van Hinsbergh VWM; Niessen HWM; Krijnen PAJ
    Ann Vasc Surg; 2017 May; 41():259-264. PubMed ID: 28163174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice.
    Schepers A; de Vries MR; van Leuven CJ; Grimbergen JM; Holers VM; Daha MR; van Bockel JH; Quax PH
    Circulation; 2006 Dec; 114(25):2831-8. PubMed ID: 17145993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic mice.
    Schepers A; Pires NM; Eefting D; de Vries MR; van Bockel JH; Quax PH
    J Vasc Surg; 2006 Apr; 43(4):809-15. PubMed ID: 16616241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice.
    Karper JC; de Vries MR; van den Brand BT; Hoefer IE; Fischer JW; Jukema JW; Niessen HW; Quax PH
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1033-40. PubMed ID: 21330606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perivenous support reduces early changes in human vein grafts: studies in whole blood perfused human vein segments.
    Stooker W; Niessen HW; Baidoshvili A; Wildevuur WR; Van Hinsbergh VW; Fritz J; Wildevuur CR; Eijsman L
    J Thorac Cardiovasc Surg; 2001 Feb; 121(2):290-7. PubMed ID: 11174734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PX-18 Protects Human Saphenous Vein Endothelial Cells under Arterial Blood Pressure.
    Kupreishvili K; Stooker W; Emmens RW; Vonk ABA; Sipkens JA; van Dijk A; Eijsman L; Quax PH; van Hinsbergh VWM; Krijnen PAJ; Niessen HWM
    Ann Vasc Surg; 2017 Jul; 42():293-298. PubMed ID: 28300679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hemodynamic forces in the ex vivo arterialization of human saphenous veins.
    Berard X; Déglise S; Alonso F; Saucy F; Meda P; Bordenave L; Corpataux JM; Haefliger JA
    J Vasc Surg; 2013 May; 57(5):1371-82. PubMed ID: 23351647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice.
    Eefting D; Bot I; de Vries MR; Schepers A; van Bockel JH; Van Berkel TJ; Biessen EA; Quax PH
    J Vasc Surg; 2009 Jul; 50(1):152-60. PubMed ID: 19563963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased infiltration of Chlamydophila pneumoniae in the vessel wall of human veins after perfusion.
    Kupreishvili K; ter Weeme M; Morré SA; van den Brule AJ; Huybregts MA; Quax PH; ten Velden J; Van Hinsbergh VW; Stooker W; Eijsman L; Niessen HW
    Eur J Clin Invest; 2008 Jul; 38(7):462-8. PubMed ID: 18489582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts.
    Wan S; Shukla N; Yim AP; Johnson JL; Angelini GD; Jeremy JY
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):494-500. PubMed ID: 17258588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Topical" HDL for vein grafts: a new solution to an old problem?
    Asmis R
    Atherosclerosis; 2011 Feb; 214(2):259-60. PubMed ID: 21146819
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease.
    Eefting D; Seghers L; Grimbergen JM; de Vries MR; de Boer HC; Lardenoye JW; Jukema JW; van Bockel JH; Quax PH
    Cardiovasc Res; 2010 Nov; 88(2):367-75. PubMed ID: 20562095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational model of blood flow in the aorto-coronary bypass graft.
    Sankaranarayanan M; Chua LP; Ghista DN; Tan YS
    Biomed Eng Online; 2005 Mar; 4():14. PubMed ID: 15745458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo (animal) models of vein graft disease.
    Schachner T; Laufer G; Bonatti J
    Eur J Cardiothorac Surg; 2006 Sep; 30(3):451-63. PubMed ID: 16870461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous C1-inhibitor production and expression in the heart after acute myocardial infarction.
    Emmens RW; Baylan U; Juffermans LJ; Karia RV; Ylstra B; Wouters D; Zeerleder S; Simsek S; van Ham M; Niessen HW; Krijnen PA
    Cardiovasc Pathol; 2016; 25(1):33-9. PubMed ID: 26476955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathologic insight into saphenous vein bypass graft disease.
    Bikdeli B; Hassantash SA; Pourabdollah M; Kalantarian S; Sadeghian M; Afshar H; Sabeti S; Marzban M; Ahmadi H; Mohammadi F
    Cardiology; 2012; 123(4):208-15. PubMed ID: 23171851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo.
    Schepers A; Eefting D; Bonta PI; Grimbergen JM; de Vries MR; van Weel V; de Vries CJ; Egashira K; van Bockel JH; Quax PH
    Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):2063-9. PubMed ID: 16825596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.